Tocilizumab for treatment of chronic active antibody-mediated rejection in kidney transplant recipients.
Boonphiphop BoonphengIris Camille C De CastroYue Harn NgChristopher D BlosserRamasamy BakthavatsalamIdoia GimferrerKelly D SmithNicolae LecaPublished in: Clinical transplantation (2023)
In our early short-term experience, TCZ appears to reduce graft injury as measured by dd-cfDNA and modulate the immune response as evident by a modest reduction in immunodominant DSA MFI. Allograft function and proteinuria also stabilized.